Workflow
Clover Health Investments(CLOV)
icon
Search documents
Clover Health Investments(CLOV) - 2023 Q4 - Earnings Call Presentation
2024-03-12 22:59
Clover Health Fourth Quarter and Full Year 2023 - Earnings Results Disclaimer | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------------------------|-------|-------|-----------------------------|-------|-------|-------|-----------------------------|-------| | | | | | | | | | | | | | In millions, except MCR | | | | | | | | | | | Revenue | | | | | | | | | | | Gross Profit | | | Fourth Quarter | | | | Full-Year | | | | | | | Revenue +12% MCR -1,000 bps | | | | Revenue +14% MCR -1,060 ...
Clover Health Investments(CLOV) - 2023 Q4 - Earnings Call Transcript
2024-03-12 22:58
Clover Health Investments, Corp. (NASDAQ:CLOV) Q4 2023 Earnings Conference Call March 12, 2024 5:00 PM ET Company Participants Ryan Schmidt - IR Andrew Toy - CEO Terrence Ronan - Interim CFO Conference Call Participants Jason Cassorla - Citi Richard Close - Canaccord Genuity Operator Ladies and gentlemen, good afternoon and welcome to the Clover Health Fourth Quarter and Full Year 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will foll ...
Clover Health Investments(CLOV) - 2023 Q4 - Annual Results
2024-03-11 16:00
Clover Health Reports Fourth Quarter and Full Year 2023 Financial Results; Delivers Continued Momentum in Financial Performance and Provides Full-Year 2024 Guidance Full-year 2023 Insurance MCR improved to 81.2% and fourth quarter MCR to 82.4% Company improves full-year 2023 Net Loss by $126.2 million and full-year Adjusted EBITDA by $245.7 million year-over-year Issues 2024 guidance with Insurance MCR range of 79% - 83% and up to $20 million of Adjusted EBITDA profitability at the high end of the range FRA ...
Industry Veteran Clay Thornton Joins Clover Health as CFO of Medicare Advantage
Newsfilter· 2024-03-07 21:05
FRANKLIN, Tenn., March 07, 2024 (GLOBE NEWSWIRE) -- Today Clover Health ("Clover" or "the Company") announced Clay Thornton as the newly appointed Chief Financial Officer of its Medicare Advantage (MA) division. Thornton, with an impressive track record spanning over a decade of healthcare financial management and operational leadership, joins as the Company enters the next phase of its lifecycle, targeting Adjusted EBITDA profitability for the full-year 20241, while emphasizing a differentiated PPO-first p ...
Clover Health Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Newsfilter· 2024-02-16 21:30
FRANKLIN, Tenn., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover" or the "Company") announced today that effective February 16, 2024, the Talent and Compensation Committee of the Company's Board of Directors granted a restricted stock unit award (the "RSUs") to a newly hired employee. The RSUs were granted under the Company's 2022 Inducement Award Plan (the "Inducement Plan") and otherwise will be subject to the terms and conditions of restricted stock unit award ag ...
3 Breakout Penny Stocks Primed for Massive Gains
InvestorPlace· 2024-01-16 14:33
In the volatile space of penny stocks, three companies are emerging as powerhouses with breakout potential, poised for massive gains. To begin with, the first one’s organic growth, the second one’s data licensing prowess in liquor retail, and the third one’s strategic insurance advancements are captivating the market. Also, the first one leads the veterinary diagnostic space with a diverse product range; the second leverages proprietary data for liquor retail dominance; and the third thrives in the insuranc ...
Clover Health Provides Business Update and Full-Year 2024 Objectives
Newsfilter· 2024-01-10 13:30
FRANKLIN, Tenn., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, announced today that it is targeting Adjusted EBITDA profitability for the full-year 2024. (1) "I believe that we are at a critical inflection point in the trajectory of our business. Throughout 2023 our results, driven by strong Insurance performance, have prove ...
PCP Use of Clover Assistant Correlated with Increased Medication Fills for Patients who Were Previously Non-Adherent
Newsfilter· 2024-01-08 22:00
FRANKLIN, Tenn., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, today released research demonstrating Clover Assistant's impact on medication adherence. The paper, Clover Assistant Use and Medication Adherence for Common Chronic Conditions, examines the correlation between Primary Care Physician (PCP) use of Clover Assistant ...
3 Medical Info Systems Stocks to Buy as Industry Rebounds
Zacks Investment Research· 2024-01-03 17:01
The past three years of health crisis have led to exponential growth in the Medical Info Systems industry, thanks to the growing demand for contactless services. In the post-pandemic era, the popularity of remote healthcare and a paperless environment have increased further. In fact, in 2023, this industry witnessed massive adoption of artificial intelligence (AI) and the Internet of Medical Things in the form of digital healthcare options in hospitals and other healthcare settings. Apart from being used fo ...
Clover Health Announces Departure of Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for 2023
2023-12-21 18:00
FRANKLIN, Tenn., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover" or the "Company") a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, today announced that Scott J. Leffler, its Chief Financial Officer, will be leaving the Company on January 26, 2024 in order to pursue another professional opportunity. Mr. Leffler noted to the Company that his departure does not reflect any disagreement with the Company on any ma ...